Patents by Inventor Markus Bürgle

Markus Bürgle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable dosage form of phenylalanine derivatives
    Patent number: 9089532
    Abstract: The invention relates to improved and stable pharmaceutical formulations of phenylalanine derivatives and the use thereof as urokinase inhibitors, particularly for the treatment of malignant tumors and tumoral metastases.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: July 28, 2015
    Assignee: Wilex AG
    Inventors: Wolfgang Schmalix, Markus Bürgle, Klaus Koch
  • Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
    Patent number: 7807681
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: October 5, 2010
    Assignee: Wilex AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS
    Publication number: 20100068272
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Application
    Filed: September 14, 2009
    Publication date: March 18, 2010
    Applicant: WILEX AG
    Inventors: Stefan SPERL, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
    Patent number: 7608623
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: October 27, 2009
    Assignee: Wilex AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
    Publication number: 20080261998
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 23, 2008
    Applicant: WILEX AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Cyclic peptidomimetic urokinase receptor antagonists
    Patent number: 7314863
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Grant
    Filed: December 30, 2005
    Date of Patent: January 1, 2008
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Buergle, Nils Potthoff, Niko Schmiedeberg
  • Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
    Publication number: 20060142305
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Application
    Filed: November 28, 2005
    Publication date: June 29, 2006
    Applicant: WILEX AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Cyclic peptidomimetic urokinase receptor antagonists
    Publication number: 20060105943
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Application
    Filed: December 30, 2005
    Publication date: May 18, 2006
    Applicant: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Buergle, Nils Potthoff, Niko Schmiedeberg
  • Cyclic peptidomimetic urokinase receptor antagonists
    Patent number: 7045504
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 16, 2006
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Buergle, Nils Potthoff, Niko Schmiedeberg
  • Cyclic peptidomimetic urokinase receptor antagonists
    Patent number: 6906032
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: June 14, 2005
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Bürgle, Nils Potthoff, Niko Schmiedeberg
  • Inhibitors for urokinase receptor
    Patent number: 6872702
    Abstract: The present invention concerns peptides as inhibitors of the binding of urokinase to the urokinase receptor. These peptides, which are preferably cyclic, are suitable as pharmaceutical agents for diseases that are mediated by urokinase and its receptor.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: March 29, 2005
    Assignee: Wilex AG
    Inventors: Horst Kessler, Heinrich Graeff, Manfred Schmitt, Viktor Magdolen, Olaf G. Wilhelm, Christoph Riemer, Markus Bürgle
  • Inhibitors for urokinase receptor
    Patent number: 6528619
    Abstract: The present invention provides peptides as inhibitors of the binding of urokinase to the urokinase receptor. The peptides have the general structural formula (I): X1-[X2]n-X3-X4-K-Y-F-X5-X6-I-X7-W-[X8]m  (I) in which X1, X2, X3, X4, X5, X6, X7 and X8 each denote an aminocarboxylic acid, n and m are each independently 0 or 1, K denotes an aminocarboxylic acid with a lysine side chain, Y denotes an aminocarboxylic acid with a tyrosine side chain, F denotes an aminocarboxylic acid with a phenyl-alanine side chain, I denotes an aminocarboxylic acid with an isoleucine side chain, W denotes an aminocarboxylic acid with a tryptophan side chain, and the monomeric building blocks are linked by —CONR1— or —NR1CO— bonds where R1 in each case independently denotes hydrogen, methyl or ethyl, and pharmaceutically compatible salts and derivatives thereof.
    Type: Grant
    Filed: January 10, 2000
    Date of Patent: March 4, 2003
    Assignee: Roche Diagnostics GmbH
    Inventors: Markus Bürgle, Heinrich Graeff, Horst Kessler, Viktor Magdolen, Bernhard König, Marcus Koppitz, Christoph Riemer, Manfred Schmitt, Ulrich Weidle